G. Murthy, G. S. Pemmaraju, N. Atallah, and E. , Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm, Leuk Res, vol.73, pp.21-23, 2018.

S. H. Swerdlow, E. Campo, and N. L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2017.

L. Pagano, C. G. Valentini, S. Grammatico, and A. Pulsoni, Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches, Br J Haematol, vol.174, issue.2, pp.188-202, 2016.

D. Roos-weil, S. Dietrich, and A. Boumendil,

, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, vol.121, issue.3, pp.440-446, 2013.

M. A. Kharfan-dabaja, T. Reljic, H. S. Murthy, E. Ayala, and A. Kumar, Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis, Clin Lymphoma Myeloma Leuk, vol.18, issue.11, pp.703-709, 2018.

S. H. Swerdlow, E. Campo, and N. L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2008.

F. Garnache-ottou, J. Feuillard, and C. Ferrand, Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia, Br J Haematol, vol.145, issue.5, pp.624-636, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00451257

F. Angelot-delettre, S. Biichle, and C. Ferrand, Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis, Cytometry A, vol.81, issue.8, pp.718-724, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00718156

L. Pagano, C. G. Valentini, and A. Pulsoni, Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study, Haematologica, vol.98, issue.2, pp.239-246, 2013.

K. A. Lyapichev, N. Sukswai, S. Konoplev, and J. D. Khoury, Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles, Ann Hematol, vol.98, issue.9, pp.2221-2222, 2019.

N. Sukswai, P. P. Aung, and C. C. Yin, Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm, Am J Surg Pathol, vol.43, issue.10, pp.1429-1437, 2019.

T. Petrella, C. J. Meijer, and S. Dalac, TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis, Am J Clin Pathol, vol.122, issue.2, pp.307-313, 2004.

F. Julia, S. Dalle, and G. Duru, Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients, Am J Surg Pathol, vol.38, issue.5, pp.673-680, 2014.

M. Ceribelli, Z. E. Hou, and P. N. Kelly, A druggable TCF4-and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm, Cancer Cell, vol.30, issue.5, pp.764-778, 2016.

K. Pulford, A. H. Banham, and L. Lyne, The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells, Leukemia, vol.20, issue.8, pp.1439-1441, 2006.

C. Cota, E. Vale, and I. Viana, Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients, Am J Surg Pathol, vol.34, issue.1, pp.75-87, 2010.

M. R. Sapienza, F. Fuligni, and C. Agostinelli, AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies' and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition, Leukemia, vol.28, issue.8, pp.1606-1616, 2014.

L. Martín-martín, A. López, and B. Vidriales, Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile, Oncotarget, vol.6, issue.22, pp.19204-19216, 2015.

D. Leroux, F. Mugneret, and M. Callanan, CD56(1) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique, Blood, vol.99, issue.1, pp.4154-4159, 2002.

Z. Tang, G. Tang, and S. A. Wang, Simultaneous deletion of 3"ETV6 and 5"EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review, Mol Cytogenet, vol.9, issue.1, p.23, 2016.

M. Lucioni, F. Novara, and G. Fiandrino, Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion, Blood, vol.118, issue.17, pp.4591-4594, 2011.

Z. Tang, Y. Li, and W. Wang, Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events, Leuk Res, vol.73, pp.86-94, 2018.

A. Emadali, N. Hoghoughi, and S. Duley, Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms, Blood, vol.127, issue.24, pp.3040-3053, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01920364

K. Suzuki, Y. Suzuki, and A. Hama, Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm, Leukemia, vol.31, issue.7, pp.1629-1633, 2017.

N. Yang, J. Huh, W. S. Chung, M. S. Cho, K. H. Ryu et al., KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm, Cancer Genet, vol.208, issue.9, pp.464-467, 2015.

Y. Takiuchi, H. Maruoka, and K. Aoki, Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia, J Clin Exp Hematop, vol.52, issue.2, pp.107-111, 2012.

Y. Fu, M. Fesler, G. Mahmud, K. Bernreuter, D. Jia et al., Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms, Cancer Genet, vol.206, issue.7-8, pp.293-298, 2013.

Y. Nakamura, H. Kayano, and E. Kakegawa, Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation, Blood Cancer J, vol.5, issue.4, p.301, 2015.

S. Kubota, K. Tokunaga, and T. Umezu, Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm, Nat Commun, vol.10, issue.1, p.3943, 2019.

, Nat Commun, vol.10, issue.1, p.1653, 2019.

H. Kodaira, S. Kobayashi, and H. Shimura, t(6;8)(p21;q24)in blastic plasmacytoid dendritic cell neoplasma, 2013.

A. Momoi, K. Toba, and K. Kawai, Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases, Leuk Res, vol.26, issue.7, pp.693-698, 2002.

K. Sakamoto, R. Katayama, and R. Asaka, Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response, Leukemia, vol.32, issue.12, pp.2590-2603, 2018.

L. Sumarriva-lezama, K. M. Chisholm, and E. Carneal, An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality, Histopathology, vol.73, issue.5, pp.767-776, 2018.

S. Harley, O. Kampagianni, A. Lee, and J. Polski, A rare case of blastic plasmacytoid dendritic cell neoplasm with aberrant immunophenotypic profile and unusual cytogenetics, Am J Clin Pathol, vol.146, 2016.

H. Kurt, J. D. Khoury, L. J. Medeiros, and Y. O. Huh, Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations, Br J Haematol, vol.181, issue.3, p.305, 2018.

P. C. Boddu, S. A. Wang, and N. Pemmaraju, 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms, Leuk Res, vol.66, pp.73-78, 2018.

M. A. Kharfan-dabaja, A. Malki, M. M. Deotare, and U. , Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study, Br J Haematol, vol.179, issue.5, pp.781-789, 2017.

T. Aoki, R. Suzuki, and Y. Kuwatsuka, Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm, Blood, vol.125, issue.23, pp.3559-3562, 2015.

D. Goren-sahin, O. M. Akay, U. Teke, H. And?c, N. Gunduz et al., Blastic plasmacytoid dendritic cell leukemia successfully treated by autologous hematopoietic stem cell transplantation to a remission of 48-month duration, Case Rep Hematol, p.471628, 2013.

L. Gilis, L. Lebras, and F. Bouafia-sauvy, Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD41/CD561 hematodermic neoplasm, Leuk Lymphoma, vol.53, issue.8, pp.1633-1637, 2012.

L. Philippe, A. Ceroi, and E. Bôle-richard, Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm, Haematologica, vol.102, issue.11, pp.1861-1868, 2017.

C. Yang, C. Fu, and Y. Feng, Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm, Ann Hematol, vol.98, issue.6, pp.1525-1527, 2019.

M. E. Agha, S. A. Monaghan, and S. H. Swerdlow, Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm, N Engl J Med, vol.379, issue.15, pp.1479-1481, 2018.

S. Grushchak, C. Joy, and A. Gray, Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report, Medicine, vol.96, issue.51, p.9452, 2017.

C. D. Dinardo, C. R. Rausch, and C. Benton, Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol, vol.93, issue.3, pp.401-407, 2018.

J. Montero, J. Stephansky, and T. Cai, Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax, Cancer Discov, vol.7, issue.2, pp.156-164, 2017.

J. Taylor, M. Haddadin, and V. A. Upadhyay, Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark, Blood, vol.134, issue.8, pp.678-687, 2019.

C. Arranto, A. Tzankov, and J. Halter, Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate, Ann Hematol, vol.96, issue.4, pp.681-682, 2017.

S. Sato, E. Tanaka, and Y. Tamai, Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate, Ann Hematol, vol.98, issue.3, pp.801-803, 2019.

S. Sukegawa, M. Sakata-yanagimoto, and R. Matsuoka, Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine

, Rinsho Ketsueki, vol.59, issue.12, pp.2567-2573, 2018.

R. Khwaja, A. Daly, M. Wong, E. Mahé, S. Cerquozzi et al., Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases, Leuk Lymphoma, vol.57, issue.11, pp.2720-2722, 2016.

K. Laribi, N. Denizon, and H. Ghnaya, Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine, Eur J Haematol, vol.93, issue.1, pp.81-85, 2014.

N. Pemmaraju, Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond, Curr Hematol Malig Rep, vol.12, issue.6, pp.510-512, 2017.

A. E. Frankel, J. H. Woo, and C. Ahn, Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients, Blood, vol.124, issue.3, pp.385-392, 2014.

W. Sun, H. Liu, and Y. Kim, First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases, J Hematol Oncol, vol.11, issue.1, p.61, 2018.

N. Pemmaraju, A. A. Lane, and K. L. Sweet, Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm, N Engl J Med, vol.380, issue.17, pp.1628-1637, 2019.

Y. Kovtun, G. E. Jones, and S. Adams, A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells, Blood Adv, vol.2, issue.8, pp.848-858, 2018.